Drug intelligence / Profile preview

ELB-245

Development stage: Discontinued
Lead developer: elbion
Modality: Small Molecules
Administration: Oral

Overview

ELB-245 is a small molecule drug that was developed by elbion AG for the treatment of overactive bladder (OAB) and urinary incontinence. It reached Phase 2 clinical trials, where it was evaluated for efficacy and safety compared to placebo and tolterodine in patients with incontinent OAB. The development of ELB-245 has since been discontinued. Its precise mechanism of action is not publicly detailed, but as a candidate for OAB, it may have targeted pathways involved in bladder control[2][3][4].

Beyond the preview

Go deeper on ELB-245.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELB-245.

Explore the full profile